Avid Bioservices Inc (CDMO)

[purpledawgs]

WH - The asco abstract stated:

"Conclusions: Bavituximab plus docetaxel achieved an encouraging response rate in advanced/metastatic breast cancer in Stage A of this study. Enrollment in Stage B of the trial is expected to be completed with preliminary results available by the annual meeting."

Either they were optimistic in the timeline to completing enrollment when they submitted the abstract, or we should get another PR. I think enrollment went a little slower than they thought it would back in January, but that is just a hunch . . .

IMO

PD